Retina/Vitreous News

Kiora Pharmaceuticals has entered into a strategic agreement that grants Théa Open Innovation development and commercialization rights to KIO-301 for the treatment of degenerative retinal diseases.

Ascendis Pharma announced the launch of Eyconis, a company formed with the exclusive rights to develop, manufacture and commercialize Ascendis’ TransCon ophthalmology assets, according to a press release.

WAILEA, Hawaii — In this Healio Video Perspective from Retina 2024, Michael A. Singer, MD, presents data on dosing intervals for faricimab as a treatment for wet age-related macular degeneration and diabetic macular edema.

Breye Therapeutics has begun dosing in its phase 1b/2a trial of oral danegaptide for treatment of diabetic macular edema, according to a company press release.

The Committee for Medicinal Products for Human Use of the European Medicines Agency issued a negative opinion on a marketing authorization application for pegcetacoplan, according to an Apellis Pharmaceuticals press release.

Worse best-corrected visual acuity, longer axial length, faster axial length elongation and severe myopic maculopathy were reported risk factors for myopic maculopathy progression in children, according to research in JAMA Ophthalmology.

Inflammasome Therapeutics announced that the first patient has been dosed in its phase 1 study of K8, a novel dual inflammasome inhibitor for treatment of diabetic macular edema.

ROME — One-year results of the phase 2 ALTITUDE trial showed efficacy and safety of a one-time in-office injection of ABBV-RGX-314 for the treatment of diabetic retinopathy.

Tilak Healthcare has released positive data from its TIL002 study of the OdySight mobile app, a vision-monitoring tool for patients with retinal diseases.

WAILEA, Hawaii — Addressing blood pressure and other underlying health concerns is critical to get the best outcomes in diabetic tractional retinal detachment surgery, according to a speaker at Retina 2024.